Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: A cross-over randomised controlled trial

Research - Open Access
George BardsleyPeter DaleyYatesAmanda BainesRodger KempsfordMathew WilliamsTony MallonIrene BraithwaiteKylie RiddellShashidhar JoshiPhilippe BareilleRichard BeasleyJames Fingleton on behalf of the study team



Fluticasone furoate/Vilanterol trifenatate (FF/VI) is an inhaled corticosteroid/long-acting beta-agonist combination with a prolonged bronchodilator duration of action. We characterised the time-course of onset and offset of airway anti-inflammatory action of FF/VI, as assessed by fraction of exhaled nitric oxide (FeNO), and compared this to the bronchodilator duration of action.


A single-centre, randomised, double-blind, placebo-controlled, two-period, crossover study was undertaken in 28 steroid-naïve adults with asthma. Participants with an FEV1 ≥ 60% predicted, reversible airway disease, and FeNO > 40 ppb received FF/VI 100/25 mcg or placebo once daily for 14 days. FeNO and peak expiratory flow were measured twice-daily during treatment and during a 21-day washout period. FEV1 was measured for five days from treatment cessation. The primary outcome measure was FeNO change from baseline ratio for 21 days following treatment cessation.


In the 27 subjects who completed the study, median (range) baseline FeNO was 87 ppb (42–212). FF/VI 100/25 mcg reduced FeNO by day 3, ratio FF/VI versus placebo 0.72 (95% confidence interval 0.61–0.86) with the maximum reduction occurring at day 14, 0.32 (0.27–0.37). Following cessation of treatment FeNO remained suppressed for 18 days, ratio on day 18 0.77 (0.59–1.00), whereas improvements in FEV1 and peak flow were maintained for 3 to 4 days post-treatment.


The anti-inflammatory duration of action of FF/VI is consistent with the high glucocorticoid receptor affinity and long lung retention of fluticasone furoate. The anti-inflammatory effect of FF/VI was of greater duration than its bronchodilator effect in adults with mild asthma.

Download PDF

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Interasma - CME:Unlocking the Door to Asthma Control: Key Factors for Therapy Selection and Medication Management
Interasma RT @EAACI_HQ: Read this article! RNA‐specific toll-like receptors #TLR are important in immunity against various pathogens but an inadequat…
Interasma RT @worldallergy: Top story: This Is Why Food Allergies Are on the Rise, According to Experts, see more https://t.c…
Interasma RT @worldallergy: WAO Tweeted Times - top stories by @ARIAGuideline, @Interasma
Interasma RT @worldallergy: Top story: POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Heal…

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA